Drug intelligence / Profile preview

epoetin + all-trans retinoic acid

Development stage: Preclinical
Lead developer: Amgen
Modality: Small Molecules, Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous, Oral, Topical

Overview

A combination therapy consisting of epoetin (a recombinant form of human erythropoietin) and all-trans retinoic acid (ATRA). Epoetin stimulates red blood cell production by promoting the division and differentiation of erythroid progenitors in the bone marrow, while ATRA induces cell differentiation through multiple pathways including the RAF-1/MEK/ERK signaling pathway. This combination has been studied for improving erythroid response in hematologic disorders, particularly in patients with myelodysplastic syndromes and acute promyelocytic leukemia.

Other names: epoetin beta + all-trans retinoic acidepoetin beta + ATRAerythropoietin beta + tretinoin

Targets

Erythropoietin ReceptorRAR (Retinoic acid receptor)

Beyond the preview

Go deeper on epoetin + all-trans retinoic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epoetin + all-trans retinoic acid.